{"id":"NCT00631657","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A 6-Month Efficacy and Safety Study of Org 50081 in Adult Patients With Chronic Primary Insomnia (21106/P05701/MK-8265-002)","officialTitle":"A 6-Month, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Outpatient Trial, Investigating the Efficacy and Safety of Org 50081 in Adult Patients With Chronic Primary Insomnia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-03-04","primaryCompletion":"2009-11-19","completion":"2009-11-19","firstPosted":"2008-03-10","resultsPosted":"2014-08-01","lastUpdate":"2018-10-02"},"enrollment":460,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Sleep Initiation and Maintenance Disorders","Mental Disorders","Dyssomnias","Sleep Disorders","Sleep Disorder, Intrinsic"],"interventions":[{"type":"DRUG","name":"Esmirtazapine","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Esmirtazapine 4.5 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To investigate the long-term efficacy and safety of treatment with esmirtazapine (Org 50081, SCH 900265, MK-8265) compared to placebo, in participants with chronic primary insomnia. Primary efficacy variable is Total Sleep Time (TST).","primaryOutcome":{"measure":"Change From Baseline in Total Sleep Time (TST) - 6-Month Treatment Period","timeFrame":"Baseline and the Mean of Weeks 14-26","effectByArm":[{"arm":"Esmirtazapine 4.5 mg","deltaMin":65.9,"sd":71.9},{"arm":"Placebo","deltaMin":19.3,"sd":62.1}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":9},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["32351205"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":342},"commonTop":["Weight increased","Somnolence","Nasopharyngitis","Headache","Increased appetite"]}}